Poster Abstract Session:
077. Use of PK/PD to optimize existing antibiotics and antifungals
Thursday, October 5, 2017: 12:30 PM-2:00 PM
Room: Poster Hall CD


Presentations:
803
Impact of minocycline, polymyxin B, meropenem, and amikacin on growth-prevention of Acinetobacter baumannii with various biofilm-forming capabilities
Maya Beganovic, Pharm.D., MPH; Megan Luther, Pharm.D.; Kathryn Daffinee, BS; Kerry LaPlante, Pharm.D., FCCP, FIDSA
Posters
  • ID Week 2017 Ab BF.pdf (1.0 MB)
  • 804
    Pharmacokinetics and Tissue Distribution of Minocycline following Intravenous Administration in Rabbits
    Vidmantas Petraitis, MD; Ruta Petraitiene, MD; Bo Bo Win Maung, MD; Tom G Nolan, PhD; David C Griffith, BA; Michael N Dudley, PharmD, FIDSA; Thomas J Walsh, MD
    806
    Pharmacokinetics of Ceftazidime/Avibactam following Intravenous Administration in Rabbits: Developing the Preclinical Foundation for Treatment of KPC-Kp Pneumonia in Immunocompromised Patients
    Vidmantas Petraitis, MD; Ruta Petraitiene, MD; Michael Satlin, MD, MS; Bo Bo Win Maung, MD; Farehin Khan, BS; Chase Mazur, BS; Benjamin Georgiades, PharmD; Joshua A Hayden, PhD; Thomas J Walsh, MD
    809
    Evaluation of Vancomycin Dosing in Intravenous Drug Users Admitted to an Internal Medicine Service
    Kristine Ferreira, Pharm.D., BCPS; Tonya Smith, Pharm.D., BCPS; Jennifer Babin, Pharm.D., BCPS; Russell Benefield, Pharm.D., BCPS (AQ-ID)
    Posters
  • Presentation #809.pdf (84.3 kB)
  • 810
    Pharmacokinetics of Daptomycin in Pediatric Intensive Care Patients
    Charalampos Antachopoulos, MD, PhD; Paschalis Kadiltzoglou, MD; Stavroula Ilia, MD, PhD; George Briassoulis, MD, PhD; Anastasia Geladari, MD; Eirini Baira, PhD; Evangelos Gikas, PhD; Efstathia Mylouli, MSc; Aristides Dokoumetzidis, PhD; Eleni Volakli, MD, PhD; Maria Sdougka, MD, PhD; Emmanuel Roilides, MD, PhD, FIDSA
    811
    Implementation of a Beta-Lactam Therapeutic Drug Monitoring Program
    Jarred Bowden, PharmD; Veena Venugopalan, PharmD; Kartikeya Cherabuddi, MD; Kenneth Klinker, PharmD
    Posters
  • ID Week Poster.pdf (4.7 MB)
  • 812
    Standard Levofloxacin Dosing May Be Insufficient in Critically Ill Trauma Patients
    Kaitlin A. Pruskowski, PharmD, BCPS, BCCCP; Kevin S. Akers, MD, FIDSA
    813
    Use of translational PKPD infection models to understand impact of neutropenia on efficacy of tedizolid phosphate
    Jianying Xiao, MD; Charles Gill, MS; Lianzhu Liang, MD; Jenny Liu, MD; Jin Wu, PhD; Christopher M. Tan, PhD; Amy Flattery, MS
    814
    Dosing Voriconazole in Obese Patients
    Ahmad Mourad, MD; Melissa Johnson, PharmD, MHS; John R Perfect, M.D., FIDSA
    815
    Correlating isavuconazole serum levels with efficacy and adverse effects (AE) among immunocompromised patients
    Pauline Kim, PharmD; Bernard Tegtmeier, PhD; Sanjeet Dadwal, MD; James Ito, MD; Jane Kriengkauykiat, PharmD
    816
    Pharmacokinetics of Tedizolid in Adults with Cystic Fibrosis
    Joshua Wang, PharmD; Jenny Park, MS; Jordanna Jayne, PhD; Timothy Bensman, PharmD, PhD; David D’Argenio, PhD; Lynn Fukushima, RN; Adupa Rao, MD; Paul Beringer, PharmD
    817
    A Novel Vancomycin Standardized Calculations Method Achieved Therapeutic Trough Goals in Obese and Non-obese Patients in a Veterans Affairs Health Care System
    Pamela Foral, Pharm.D., BCPS; Brian Dalke, Pharm.D.; Ashley Brondum, Pharm.D.; Michaela Hrdy, Pharm.D.; John Horne, MD; Christopher Destache, PharmD
    Posters
  • Vanco_poster_ID_week.pdf (466.6 kB)
  • 818
    Evaluation of early achievement of an AUC/MIC of >400 for Vancomycin in children with methicillin-resistant Staphylococcus aureus bacteremia
    Takemi Murai, MD, PhD; Hiroshi Higuchi, N/A; Junichi Suwa, PharB, MS; Hanako Funakoshi, MD; Ryuu Yoneda, MD; Sho Ishii, MD; Kotaro Araki, MD; Kahoru Fukuoka, MD; Yuta Aizawa, MD, PhD; Yuho Horikoshi, MD
    Posters
  • ID week2017 MRSA.png (1019.0 kB)
  • 819
    Spatio-temporal Activity of Human-Simulated Exposures of Meropenem (MEM) and Ceftolozane (TOL) on Pseudomonas aeruginosa Biofilms
    Srijay Rajan, BS; Davide Verotta, Ph.D.; Christina Sutherland, BS; David P. Nicolau, PharmD, FCCP, FIDSA; Alfred Spormann, PhD; Katherine Yang, PharmD, MPH
    820
    Vancomycin Prescribing Habits – Are We Still Afraid of Mississippi Mud?
    Catharine C. Bulik, Pharm.D.; Justin C. Bader, Pharm.D., MBA; Sujata M. Bhavnani, Pharm.D., M.S.; Christopher M. Rubino, Pharm.D.; Kim L. Sweeney, Pharm.D.; Paul G. Ambrose, Pharm.D., FIDSA; Robert C. Owens Jr., Pharm.D.
    821
    Clearance of ceftazidime-avibactam in an in vitro continuous venovenous hemodialysis model
    Kristen L. Bunnell, PharmD; Eric Wenzler, PharmD; Larry H. Danziger, Pharm.D., FIDSA; Keith A. Rodvold, Pharm.D., FIDSA
    822
    Relationship between Vancomycin Area Under the Concentration-Time Curve (AUC) and Nephrotoxicity in Adults
    David Allen, PharmD, BCPS; Mary Townsend, PharmD, AAHIVP; Richard Drew, PharmD, MS, FCCP, FIDP
    823
    Genetic Polymorphisms influencing Low Posaconazole Plasma Concentration in Patients with Hematologic malignancies
    Hyeon Jeong Suh, MD; Eunyoung Lee, M.D.; Kyoung-Ho Song, MD; Pyeong-Gyun Choe, MD; Ji Whan Bang, MD; Eu Suk Kim, MD; Hong Bin Kim, MD, PhD; Sang Won Park, M.D., Ph.D.; Nam Joong Kim, MD, PhD; Wan Beom Park, MD; Myoung-Don Oh, M.D., Ph.D.
    825
    Plasma Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Subjects with Cystic Fibrosis
    Kajal Larson, PhD; John S. Bradley, MD, FIDSA, FPIDS, FAAP; Antonio Arrieta, MD, FIDSA; Shan Yang, PhD; Brian Yu, PharmD; Matthew G Johnson, MPH; Matthew Rizk, PhD; Elizabeth Rhee, MD
    826
    Incidence of Nephrotoxicity Among Patients Initiated on Vancomycin and Beta-lactam Combination Therapies
    Megha Shah, PharmD; Suraj Rajasimhan, PharmD, BCPS; Tiffany Bias, PharmD, BCPS, AAHIVP
    827
    Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
    Andreas H. Groll, MD; Hisham Abdel-Azim, MD, MS; Thomas Lehrnbecher, MD; William Steinbach, MD; RoseAnn Murray, PhD; Amanda Paschke, MD, MSCE; Eric Mangin, MS; Gregory A. Winchell, MD; Christopher J. Bruno, MD
    Posters
  • ID Week_Groll_Poster 827.pdf (254.6 kB)
  • 828
    Real World Evaluation of Ceftolozane/Tazobactam (C/T) Use and Clinical Outcomes at an Academic Medical Center in Las Vegas
    Kimberly D. Leuthner, PharmD, FIDSA; Ravina Kullar, Pharm.D., M.P.H.; Becky Jayakumar, PharmD; David A. Hewlett, PharmD; Truong Nguyen, PharmD Candidate; Laura Puzniak, PhD, MPH
    Posters
  • IDW 2017 Las Vegasv Final.pdf (144.0 kB)
  • 830
    Clinical Manifestations and Outcome of Fluoroquinolone Associated Acute Interstitial Nephritis
    Saira Farid, MD; Omar AbuSaleh, MD; Maryam Mahmood, MD; Zerelda Esquer Garrigos, MD; Abdurrahman Hamadah, MD; Samih Nasr, MD; Nelson Leung, MD; M. Rizwan Sohail, MD
    831
    Traditional PK-PD Indices for Efficacy – Can We Do Better?
    Elizabeth A. Lakota, Pharm.D., M.S.; Justin C. Bader, Pharm.D., MBA; Sujata M. Bhavnani, Pharm.D., M.S.; David R. Andes, M.D., FIDSA; Paul G. Ambrose, Pharm.D., FIDSA
    832
    At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
    Justin C. Bader, Pharm.D., MBA; Catharine C. Bulik, Pharm.D.; Sujata M. Bhavnani, Pharm.D., M.S.; Christopher M. Rubino, Pharm.D.; Kim L. Sweeney, Pharm.D.; Paul G. Ambrose, Pharm.D., FIDSA; Robert C. Owens Jr., Pharm.D.
    833
    Breaking New Ground: An Evaluation of Susceptibility Breakpoints for Echinocandins against Candida Species 
    Justin C. Bader, Pharm.D., MBA; David R. Andes, M.D., FIDSA; Mariana Castanheira, PhD; Paul G. Ambrose, Pharm.D., FIDSA; Sujata Bhavnani, Pharm.D., M.S.
    835
    Impact of an Extended Infusion Beta-lactam Strategy on Outcomes in Critically Ill Patients with Pseudomonas Infections
    Kenneth Klinker, PharmD; Veena Venugopalan, PharmD; Andrea Carnley, PharmD Candidate; Stacy Voils, PharmD; Jessica Cope, PharmD; Kartikeya Cherabuddi, MD
    Posters
  • EI poster IDweek 2017.pdf (437.1 kB)
  • 836
    Influence of Polymyxin B Dose on Development and Recovery of Acute Kidney Injury
    Lydia D'Agostino, PharmD, BCPS; Elena Martin, BS; Michael Yin, MD; Christine J. Kubin, PharmD BCPS (AQ-ID)
    838
    Creation and Validation of a Pediatric Vancomycin Nomogram for a Goal Trough of 10-15 mg/L at a Quaternary Care Children’s Hospital
    Philip Lee, Pharm D.; Jessica Frye, PharmD; Xing Chen, PharmD; Susanna Chang, PharmD; Birender Singh, PharmD; Vijaya Soma, MD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™


    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.